JP2018511643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511643A5 JP2018511643A5 JP2017554403A JP2017554403A JP2018511643A5 JP 2018511643 A5 JP2018511643 A5 JP 2018511643A5 JP 2017554403 A JP2017554403 A JP 2017554403A JP 2017554403 A JP2017554403 A JP 2017554403A JP 2018511643 A5 JP2018511643 A5 JP 2018511643A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- composition
- paclitaxel
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930012538 Paclitaxel Natural products 0.000 claims description 40
- 229960001592 paclitaxel Drugs 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 26
- -1 paclitaxel compound Chemical class 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 206010033128 Ovarian cancer Diseases 0.000 claims description 16
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 16
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 14
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 14
- 201000002528 pancreatic cancer Diseases 0.000 claims description 14
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
- 201000005202 lung cancer Diseases 0.000 claims description 12
- 208000020816 lung neoplasm Diseases 0.000 claims description 12
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 10
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 10
- 230000004083 survival effect Effects 0.000 claims description 8
- 230000003442 weekly effect Effects 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000009104 chemotherapy regimen Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 34
- 239000003814 drug Substances 0.000 claims 3
- 229940123237 Taxane Drugs 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149349P | 2015-04-17 | 2015-04-17 | |
| US62/149,349 | 2015-04-17 | ||
| US201662280947P | 2016-01-20 | 2016-01-20 | |
| US62/280,947 | 2016-01-20 | ||
| PCT/US2016/028177 WO2016168856A1 (en) | 2015-04-17 | 2016-04-18 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018511643A JP2018511643A (ja) | 2018-04-26 |
| JP2018511643A5 true JP2018511643A5 (https=) | 2019-04-25 |
Family
ID=55854799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554403A Pending JP2018511643A (ja) | 2015-04-17 | 2016-04-18 | 癌を治療するための方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180085341A1 (https=) |
| EP (1) | EP3283069A1 (https=) |
| JP (1) | JP2018511643A (https=) |
| KR (1) | KR20180006918A (https=) |
| CN (1) | CN107666906A (https=) |
| AU (1) | AU2016247319A1 (https=) |
| BR (1) | BR112017022281A2 (https=) |
| CA (1) | CA2983010A1 (https=) |
| EA (1) | EA201792287A1 (https=) |
| HK (1) | HK1250944A1 (https=) |
| IL (1) | IL255022A0 (https=) |
| MX (1) | MX2017013360A (https=) |
| PH (1) | PH12017501879A1 (https=) |
| SG (2) | SG10201900564WA (https=) |
| TW (1) | TW201713327A (https=) |
| WO (1) | WO2016168856A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3050566B1 (en) | 2007-09-10 | 2018-11-28 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| EP2983790A2 (en) | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2017132049A1 (en) * | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Methods for treating cancer |
| JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
| CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| CN111093660A (zh) * | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| EP3865130A4 (en) * | 2018-10-12 | 2022-07-20 | 1Globe Biomedical Co., Ltd. | NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER |
| EP3705893A1 (en) * | 2019-03-05 | 2020-09-09 | Humanitas Mirasole S.p.A. | Methods to assess the risk of being affected by prostate cancer |
| WO2020197505A1 (en) * | 2019-03-27 | 2020-10-01 | Singapore Health Services Pte Ltd | Biomarker with therapeutic implications for peritoneal carcinomatosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3050566B1 (en) * | 2007-09-10 | 2018-11-28 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| EP2547205B1 (en) | 2010-03-19 | 2024-03-20 | 1Globe Biomedical Co., Ltd. | Novel methods for targeting cancer stem cells |
| RU2571661C2 (ru) | 2010-03-19 | 2015-12-20 | Бостон Байомедикал, Инк. | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
| US9150530B2 (en) | 2011-03-04 | 2015-10-06 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies |
| US8977803B2 (en) | 2011-11-21 | 2015-03-10 | Western Digital Technologies, Inc. | Disk drive data caching using a multi-tiered memory |
| WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
| EP2983790A2 (en) | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2017132049A1 (en) * | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Methods for treating cancer |
-
2016
- 2016-04-18 US US15/566,919 patent/US20180085341A1/en not_active Abandoned
- 2016-04-18 JP JP2017554403A patent/JP2018511643A/ja active Pending
- 2016-04-18 BR BR112017022281A patent/BR112017022281A2/pt not_active Application Discontinuation
- 2016-04-18 TW TW105112097A patent/TW201713327A/zh unknown
- 2016-04-18 EP EP16723854.2A patent/EP3283069A1/en not_active Withdrawn
- 2016-04-18 HK HK18110438.9A patent/HK1250944A1/zh unknown
- 2016-04-18 KR KR1020177033135A patent/KR20180006918A/ko not_active Withdrawn
- 2016-04-18 AU AU2016247319A patent/AU2016247319A1/en not_active Abandoned
- 2016-04-18 SG SG10201900564WA patent/SG10201900564WA/en unknown
- 2016-04-18 CN CN201680032355.6A patent/CN107666906A/zh active Pending
- 2016-04-18 SG SG11201708504XA patent/SG11201708504XA/en unknown
- 2016-04-18 EA EA201792287A patent/EA201792287A1/ru unknown
- 2016-04-18 WO PCT/US2016/028177 patent/WO2016168856A1/en not_active Ceased
- 2016-04-18 CA CA2983010A patent/CA2983010A1/en not_active Abandoned
- 2016-04-18 MX MX2017013360A patent/MX2017013360A/es unknown
-
2017
- 2017-10-15 IL IL255022A patent/IL255022A0/en unknown
- 2017-10-18 PH PH12017501879A patent/PH12017501879A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511643A5 (https=) | ||
| JP2019506392A5 (https=) | ||
| MX2016006919A (es) | Nucleotidos para el tratamiento de cancer de higado. | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| WO2015154064A3 (en) | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | |
| JP2008535902A5 (https=) | ||
| JP2015533176A5 (https=) | ||
| CN101355936B (zh) | 包含cdk抑制剂和生长因子抗体或抗有丝分裂剂的组合 | |
| JP2019507721A5 (https=) | ||
| IL308009A (en) | Methods of treating cancers having a biallelic loss of function or gene overexpression mutation | |
| JP2018525358A5 (https=) | ||
| MX385704B (es) | Derivado de heteroarilo o su sal farmacéuticamente aceptable, su método de preparación y composición farmacéutica para la prevención o tratamiento de enfermedades asociadas con pi3 cinasas que contiene el mismo como ingrediente activo. | |
| RU2011142806A (ru) | Комбинации пентамидина для лечения рака | |
| NZ726365A (en) | Combinations for treating cancers | |
| JP2021514395A5 (https=) | ||
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| JP2020512977A5 (https=) | ||
| MX393711B (es) | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres | |
| IL276407B1 (en) | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent | |
| JP2017507175A5 (https=) | ||
| JP2019534865A5 (https=) | ||
| JP2018534256A5 (https=) | ||
| Lv et al. | Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold |